Safety, Eligibility, and Provider Guidance Before Starting Oral Semaglutide Tablets Oral semaglutide is not suitable for everyone
That frustration, that feeling of defeat, is more common than you think
What do GLP-1 medications do to your nutrition needs
The gut microbiota metabolite SCFAs are one of the effective targets for ameliorating NAFLD
Whole-genome sequencing of phenotypically distinct inflammatory breast cancers reveals similar genomic alterations to non-inflammatory breast cancers
Lillys eloralintide (amylin receptor agonist), providing a potential option for Lilly to defend against amylin analogues, including Novo Nordisks CagriSema, which combines dual amylin and calcitonin receptor agonist cagrilintide and semaglutide, or Zealands petrelintide (phase 2) Structure Therapeutics GSBR-1290 (GLP-1), small molecule, oral obesity therapy, seeking to substantiate its earlier, positive phase 2a data to deliver competitive weight loss, against both other oral therapies and marketed injectables, with acceptable tolerability (phase 2b) Crucially, a number of phase 3 readouts in 2025 for key AOM assets will set the stage for their launch in 2026, when the next wave of AOMs enter the market to re-shape the competitive landscape: Lillys orforglipron (GLP-1), one of the first oral AOMs to launch, possibly alongside oral semaglutide, and when it does, the first small molecule based therapy in the market
